Large pharma companies spell out reasons why tariffs will harm US investments
The first wave of biopharma comments on industry-specific tariffs is here.
As of Thursday morning, just over 300 of at least 950 public comments have …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
